Jian Jie, Wei Meng, Li Xumei, Xiong Qian, Xiang Jiangming, Zhao Shengping, Peng Yuxi, Huang Jingjing
Department of Pathology, Chongqing Changshou District Maternal and Child Health Hospital, Chongqing, China.
Department of Surgery, Chongqing Changshou District Maternal and Child Health Hospital, Chongqing, China.
Front Endocrinol (Lausanne). 2025 May 22;16:1551075. doi: 10.3389/fendo.2025.1551075. eCollection 2025.
Patients with N1b papillary thyroid carcinoma (PTC) was associated with a worse prognosis. The prognostic role of positive lymph nodes (PLN) and whether postoperative radioactive iodine (RAI) therapy conferred a survival benefit were debatable issues in these patients.
Data were drawn from the SEER database for PTC patients with clinical N1b disease diagnosed between 2004-2015. All patient underwent total thyroidectomy with or without RAI. Patients were categorized by age (≥55 years and <55 years) and analyzed based on PLN. Propensity score matching (PSM) were used to balance characteristics between patients who did and did not receive RAI therapy. Overall survival (OS) was the primary outcome. Kaplan-Meier survival analysis and Cox analysis were performed.
A total of 4343 N1b PTC patients were included, with 884 patients aged ≥55 years and 3459 patients aged <55 years. In patients aged ≥55 years, the optimal PLN cutoff for risk stratification was 8. Those with PLN ≥9 had significantly lower 5-year (83.7% vs. 90.1%), 10-year (67.4% vs. 78.8%) and 15-year (50.3% vs. 59.5%) OS rates. After adjusting, the hazard ratio for death in the PLN ≥9 group increased by 30%. After PSM, in subgroup of aged ≥55 years and PLN ≥9, the survival benefit was notable in those received RAI therapy. In contrast, for patients aged ≥55 years and PLN ≤8 or aged <55 years, no survival difference was found between those received RAI and those not.
In N1b PTC patients aged ≥55 years, PLN ≥9 predicted a poorer survival. Postoperative RAI therapy offered survival benefits for this subgroup.
N1b 期甲状腺乳头状癌(PTC)患者预后较差。阳性淋巴结(PLN)的预后作用以及术后放射性碘(RAI)治疗是否能带来生存获益,在这些患者中仍是有争议的问题。
数据来源于监测、流行病学和最终结果(SEER)数据库,纳入2004年至2015年期间诊断为临床N1b期疾病的PTC患者。所有患者均接受了全甲状腺切除术,部分患者接受了RAI治疗。患者按年龄(≥55岁和<55岁)分类,并根据PLN进行分析。采用倾向评分匹配(PSM)来平衡接受和未接受RAI治疗患者的特征。总生存期(OS)是主要结局指标。进行了Kaplan-Meier生存分析和Cox分析。
共纳入4343例N1b期PTC患者,其中884例年龄≥55岁,3459例年龄<55岁。在年龄≥55岁的患者中,风险分层的最佳PLN截断值为8。PLN≥9的患者5年(83.7%对90.1%)、10年(67.4%对78.8%)和15年(50.3%对59.5%)总生存率显著较低。调整后,PLN≥9组的死亡风险比增加了30%。PSM后,在年龄≥55岁且PLN≥9的亚组中,接受RAI治疗的患者生存获益显著。相比之下,对于年龄≥55岁且PLN≤8或年龄<55岁的患者,接受RAI治疗和未接受RAI治疗的患者之间未发现生存差异。
在年龄≥55岁的N1b期PTC患者中,PLN≥9预示着较差的生存率。术后RAI治疗为该亚组患者带来了生存获益。